Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

Abstract

An analysis of the activity of compounds tested in pre-clinical in vivo and in vitro assays by the National Cancer Institute's Developmental Therapeutics Program was performed. For 39 agents with both xenograft data and Phase II clinical trials results available, in vivo activity in a particular histology in a tumour model did not closely correlate with activity in the same human cancer histology, casting doubt on the correspondence of the pre-clinical models to clinical results. However, for compounds with in vivo activity in at least one-third of tested xenograft models, there was correlation with ultimate activity in at least some Phase II trials. Thus, an efficient means of predicting activity in vivo models remains desirable for compounds with anti-proliferative activity in vitro. For 564 compounds tested in the hollow fibre assay which were also tested against in vivo tumour models, the likelihood of finding xenograft activity in at least one-third of the in vivo models tested rose with increasing intraperitoneal hollow fibre activity, from 8% for all compounds tested to 20% in agents with evidence of response in more than 6 intraperitoneal fibres (P< 0.0001). Intraperitoneal hollow fibre activity was also found to be a better predictor of xenograft activity than either subcutaneous hollow fibre activity or intraperitoneal plus subcutaneous activity combined. Since hollow fibre activity was a useful indicator of potential in vivo response, correlates with hollow fibre activity were examined for 2304 compounds tested in both the NCI 60 cell line in vitro cancer drug screen and hollow fibre assay. A positive correlation was found for histologic selectivity between in vitro and hollow fibre responses. The most striking correlation was between potency in the 60 cell line screen and hollow fibre activity; 56% of compounds with mean 50% growth inhibition below 10(-7.5) M were active in more than 6 intraperitoneal fibres whereas only 4% of compounds with a potency of 10(-4) M achieved the same level of hollow fibre activity (P< 0.0001). Structural parameters of the drugs analysed included compound molecular weight and hydrogen-bonding factors, both of which were found to be predictive of hollow fibre activity.

References 11

1. 1.

   Alley M. C., Scudiero D. A., Monks A., Hursey M. L., Czerwinski M. J., Fine D. L., Abbott B. J., Mayo J. G., Shoemaker R. H., Boyd M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988;48(3):589-601.

   Not in our library

2. 2.

   Ghose A. K., Viswanadhan V. N., Wendoloski J. J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem. 1999;1(1):55-68.

   Not in our library10.1021/cc9800071

3. 3.

   Hahnfeldt P., Panigrahy D., Folkman J., Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 1999;59(19):4770-4775.

   Not in our library

4. 4.

   History of the Cancer Chemotherapy Program. Cancer Chemother Rep. 1966;50(7):349-396.

   Not in our library

5. 5.

   Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991;83(11):757-766.

   Not in our library10.1093/jnci/83.11.757

6. 6.

   Paull K. D., Shoemaker R. H., Hodes L., Monks A., Scudiero D. A., Rubinstein L., Plowman J., Boyd M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst. 1989;81(14):1088-1092.

   Not in our library10.1093/jnci/81.14.1088

7. 7.

   Phillips R. M., Pearce J., Loadman P. M., Bibby M. C., Cooper P. A., Swaine D. J., Double J. A. Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs. Cancer Res. 1998;58(23):5263-5266.

   Not in our library

8. 8.

   Sausville E. A., Feigal E. Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA. Ann Oncol. 1999;10(11):1287-1291.

   Not in our library10.1023/a:1008333901925

9. 9.

   Scholz C. C., Berger D. P., Winterhalter B. R., Henss H., Fiebig H. H. Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts. Eur J Cancer. 1990;26(8):901-905.

   Not in our library10.1016/0277-5379(90)90196-z

10. 10.

    Venditti J. M. Preclinical drug development: rationale and methods. Semin Oncol. 1981;8(4):349-361.

    Not in our library

11. 11.

    Venditti J. M., Wesley R. A., Plowman J. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. Adv Pharmacol Chemother. 1984;20:1-20.

    Not in our library10.1016/s1054-3589(08)60263-x

Cited by papers we hold 12

• Patient-derived xenograft models in cancer therapy: technologies and applications · 2023
  No notice
• Patient-derived xenograft (PDX) models, applications and challenges in cancer research · 2022
  No notice
• Mouse models of glioblastoma for the evaluation of novel therapeutic strategies · 2021
  No notice
• Characterization and comparison of genomic profiles between primary cancer cell lines and parent atypical meningioma tumors · 2020
  Not checked
• The role of mouse tumour models in the discovery and development of anticancer drugs · 2019
  No notice
• Osteosarcoma: Accelerating Progress Makes for a Hopeful Future · 2018
  No notice
• Current status and perspectives of patient-derived xenograft models in cancer research · 2017
  No notice
• Patient-derived xenograft models of breast cancer and their predictive power · 2015
  No notice
• Generation of Multicellular Tumor Spheroids with Microwell-Based Agarose Scaffolds for Drug Testing · 2015
  No notice
• Next generation patient-derived prostate cancer xenograft models · 2014
  Not checked
• Multiplexing Spheroid Volume, Resazurin and Acid Phosphatase Viability Assays for High-Throughput Screening of Tumour Spheroids and Stem Cell Neurospheres · 2014
  No notice
• Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model · 2009
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.